Guided by collaboration with healthcare partners and insight into prescribing trends, these formulations are designed to help address gaps where commercially available options may not meet specific patient requirements
Preoperative Administration of the 5-HT4 Receptor Agonist Prucalopride Reduces Intestinal Inflammation and Shortens Postoperative Ileus via Cholinergic Enteric Neurons
The following table provides a summary of available brand doses and how they are administered: | Brand Name | Active Ingredient | Available Doses | How Its Taken | |------------|-------------------|------------------------------------------------|------------------| | Saxenda | Liraglutide | 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg | Daily injection | | Victoza | Liraglutide | 0.6 mg, 1.2 mg, 1.8 mg | Daily injection | | Ozempic | Semaglutide | 0.25 mg, 0.5 mg, 1 mg, 2 mg | Weekly injection | | Wegovy | Semaglutide | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg | Weekly injection | | Rybelsus | Semaglutide | 3 mg, 7 mg, 14 mg | Daily tablet | Practical tradeoffs, stated plainly
Their major limitation is a lack of control over nutrients and gas exchange and waste disposal, which was overcome in microfluidic liver-on-chip platforms enabling automated control over these factors
